BN Business News
会社を追加 →
この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。

ビジネス · 1994/2/181 分で読めます

Opportunity for a Cooperative Research and Development Agreement (CRADA) for Development of an Immortalized Fetal Glial Cell Line as a Delivery System for Treatment of Various Neurological Disorders

ローカル自動翻訳 · 情報源の原言語

概要

The National Institutes of Health, (NIH) seeks an agreement with a company(ies) which will assist in the further development and commercialization of an immortalized fetal glial cell line for its use as a delivery system for recombinant proteins, drugs, and other pharmaceutical therapeutics for the treatment of various neurological disorders. The National Institute of Neurological Disorders and Stroke (NINDS) believes the technology can be utilized in the treatment of several neurological disorders. The NINDS reserves the right to entertain the possibility of being involved in CRADAs with multiple Companies for the co-development of this delivery system for its use in different neurological disorders.

情報源の原言語: Federal Register — Health and Human Services原文の発表を開く →

関連インサイト

ビジネスインサイト →